Clinical-stage biopharmaceutical company, Anavex Life Sciences Corp(OTCMKTS:AVXL), which is developing drug candidates for treating Alzheimer’s as well as other central nervous system diseases, various types of cancer and pain, has launched fresh promising preclinical data for both ANAVEX 3-71 and ANAVEX 2-73 at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Nice, France.
In first presentation, member of the Anavex Scientific Advisory Board, Tangui Maurice, PhD, showed for the first time the vital role of sigma-1 receptor on survival and memory in the presence of amyloid.
Amyloid can play an important role in growth of the symptoms of Alzheimer’s disease.
ANAVEX 2-73 is presently undergoing Phase 2a trial in Alzheimer’s patients. On the other hand, second presentation was given by Abraham Fisher, PhD, a member of the Anavex Scientific Advisory Board. It showed a data showing ANAVEX 3-71 rescuing mushroom synaptic or spine loss in hippocampal neurons of wild type and two mouse models of AD.
It was clear that ANAVEX 3-71 also reduced tau phospho-epitopes AT100, AT8 AT180, AT270, PHF-1 and decreased kinases inducing tau-hyperphosphorylation along with decreasing mitigated cognitive impairments in 3xTg-AD animal model.
Therefore, ANAVEX 3-71 may restore synaptic homeostasis, by decreasing p25 and inhibiting GSK3beta & Cdk5.
There is a belief that effects of ANAVEX 3-71 are mediated by activation of the M1 muscarinic receptor (M1R) as well as S1R via an induced hypothetical heteromerization between M1R & S1R.
Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, stated that the new data is encouraging and the company is looking forward to the progress in the next quarter.
The drug ANAVEX 3-71 may give therapeutic advantages in Alzheimer’s and other protein-aggregation-related diseases because it can increase neuroprotection as well as cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.